Plodicitinib is a JAK3/TFK inhibitor targeting key pathogenic mechanisms of autoimmune diseases. It suppresses T- and B-cell activation and differentiation by inhibiting JAK3 and Tec family kinases, including BTK and ITK, thereby reducing autoantibody production and exerting therapeutic effects in autoimmune and inflammatory diseases.

Importantly, Plodicitinib demonstrates selectivity against targets associated with increased safety risks, including EGFR, JAK1, and JAK2.

* TFK : Tec Family kinase (includes BTK and ITK)
* Yc : common gamma chain